Breaks Categories: News

TuesdayAug 16, 2022 1:13 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Key Management Positions

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, have announced advanced appointments for two key executives. According to the company, Delic Holdings cofounder and CEO Matt Stang has been named executive chair while COO Kevin Nicholson has been named CEO and will also join the company’s board of directors; Nicholson will continue to serve in his current role as CEO of Ketamine Wellness Centers (“KWC”). Before founding Delic, Stang owned and operated “High Times,”a leading source of cannabis news. As Delic CEO, Stang led the company in its acquisition of…

Continue Reading

TuesdayAug 16, 2022 11:45 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information…

Continue Reading

TuesdayAug 09, 2022 11:57 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the shares can be sold “from time to time” through the Neo Exchange, the NYSE American LLC or any other “marketplace” upon which the shares are listed, quoted or traded, at the prevailing market price at the time of sale. The company anticipates using any proceeds from the sales of these shares for growth opportunities and working capital initiatives. In addition, Cybin…

Continue Reading

MondayAug 01, 2022 10:46 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Debenture Offering

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has completed the sale of 1,240 units, with each unit consisting of one 4% senior secured $1,064 ‎principal amount convertible debenture and 16,369 share purchase warrants. The sale, which was resulted in gross proceeds of $1,240,000 for the company, was completed on July 27, 2022. According to the announcement, the principal amount and accrued but unpaid interest on each debenture is ‎convertible into common shares of the company; that conversion is done at the option of the holder at any ‎time following the…

Continue Reading

ThursdayJul 28, 2022 10:56 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit https://ibn.fm/ghBjR To view…

Continue Reading

WednesdayJul 27, 2022 10:43 am

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Study Evaluating Topically Administered Ketamine Formulation

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, has reported that its recent animal study evaluating topically administered ketamine reached a positive end point: using SILO’s selected formulation and partnered, patented delivery system, the study indicated reversal of allodynia and hyperalgesia. According to the announcements, the proprietary formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, with mechanical hyperalgesia reduced on day seven at the pre-dose time point. In short, the company reported, the results indicate that the dosing of ketamine using a patent-protected delivery system designed by Silo Pharma Zylo Therapeutics showed positive results…

Continue Reading

TuesdayJul 26, 2022 12:13 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled its annual shareholder meeting. The company’s 2022 Annual Meeting of Shareholders will begin at 10 a.m. ET on Aug. 15, 2022; the meeting will be held virtually. According to the announcement, notice of the annual meeting and a proxy statement containing meeting details should be available approximately July 25, 2022; individuals who were shareholders of record at close of business on July 11, 2022, will have access to the information. The company noted that meeting materials will be mailed to shareholders, and the information…

Continue Reading

ThursdayJul 21, 2022 11:26 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reports on First Full-Year Revenue, Issues KWC Status Update

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has released an update on its both its financial and corporate status. According to the announcement, the company released its first end-of-year earnings report in May, which showed $1.5 million annual revenue and a growth in net assets from $2.1 million in 2020 to $10 million by 2021 year end, a 500% year-over-year increase. In addition, the company’s Ketamine Wellness Centers (“KWC”) are reporting impressive growth, offering an estimated 100,000 treatments so far at its 13 operational, state-of-the-art clinics; the company…

Continue Reading

WednesdayJul 20, 2022 12:40 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs’ Dr. Markus Roggen to Cannabis Scientist Power List

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of work on cannabis research that will have a positive, lasting effect on the industry, Dr. Roggen is consistently recognized as one of the most influential figures in the processing professionals category. Under Dr. Roggen’s leadership, Delic Labs will transfer its cannabis sector expertise and experience…

Continue Reading

WednesdayJul 13, 2022 2:30 pm

PsychedelicNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that is wholly owned subsidiary, Lucid Psycheceuticals Inc., filed a provisional patent application on novel formulations of palmitoylethanolamide (“PEA”). According to the update, the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma. The company is diligently pursuing the clinical development of FSD201 for various indications. FSD Pharma recently announced the submission of an Investigational New Drug…

Continue Reading